Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 11

1.

Nephroprotective strategies in septic shock: the VANISH trial.

Kwon S, Crowley G, Haider SH, Zhang L, Nolan A.

J Thorac Dis. 2016 Nov;8(11):E1508-E1510. doi: 10.21037/jtd.2016.11.44. No abstract available.

2.

Treatment and management of ascites and hepatorenal syndrome: an update.

Lenz K, Buder R, Kapun L, Voglmayr M.

Therap Adv Gastroenterol. 2015 Mar;8(2):83-100. doi: 10.1177/1756283X14564673. Review.

3.

Therapeutic response to vasoconstrictors in hepatorenal syndrome parallels increase in mean arterial pressure: a pooled analysis of clinical trials.

Velez JC, Nietert PJ.

Am J Kidney Dis. 2011 Dec;58(6):928-38. doi: 10.1053/j.ajkd.2011.07.017. Epub 2011 Sep 29.

4.

Comparison of the effect of midodrine versus octreotide on hemodynamic status in cirrhotic patients with ascites.

Minakari M, Faiiaz L, Rowshandel M, Shavakhi A.

J Res Med Sci. 2011 Jan;16(1):87-93.

5.

Renal haemodynamics and function following partial portal decompression.

Ross S, Thometz D, Serafini F, Bloomston M, Morton C, Zervos E, Rosemurgy A.

HPB (Oxford). 2009 May;11(3):229-34. doi: 10.1111/j.1477-2574.2009.00040.x.

6.

Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis.

Salerno F, Gerbes A, Ginès P, Wong F, Arroyo V.

Gut. 2007 Sep;56(9):1310-8. Epub 2007 Mar 27. Review. No abstract available.

7.

Renal dysfunction in cirrhosis: diagnosis, treatment and prevention.

Yeung E, Yong E, Wong F.

MedGenMed. 2004 Dec 2;6(4):9. Review. No abstract available.

8.

The hepatorenal syndrome.

Dagher L, Moore K.

Gut. 2001 Nov;49(5):729-37. Review. No abstract available.

9.

Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study.

Brensing KA, Textor J, Perz J, Schiedermaier P, Raab P, Strunk H, Klehr HU, Kramer HJ, Spengler U, Schild H, Sauerbruch T.

Gut. 2000 Aug;47(2):288-95.

10.

Is there still a need for albumin infusions to treat patients with liver disease?

Ginès P, Arroyo V.

Gut. 2000 May;46(5):588-90. No abstract available.

11.

Effect of meal induced splanchnic arterial vasodilatation on renal arterial haemodynamics in normal subjects and patients with cirrhosis.

Iwao T, Oho K, Nakano R, Yamawaki M, Sakai T, Sato M, Miyamoto Y, Toyonaga A, Tanikawa K.

Gut. 1998 Dec;43(6):843-8.

Supplemental Content

Support Center